(Reuters) – Reckitt Benckiser Group raised Tuesday its full-year outlook after reporting stronger-than-expected sales for the third quarter. This was due to price increases and a surge in demand for Mucinex cold/flu remedies, as well as sexual wellness products.

Lysol, a manufacturer of cleaning products, reported an unexpected 3.3% increase in like-for–like sales during the third quarter. That’s more than 0.7% less than analysts had anticipated, according to a company report.

These sales were not included in the reported numbers and estimates.

However, the company raised its like-for-like full-year revenue growth projection to 1-3%. This was a change from flat to up to 2% earlier.

Reckitt reported that raw material prices have increased 10%, which is a significant increase from the previous 8-9% estimate. Reckitt cites challenges in particular in surfactants and paper, as well as tinplate because of the rising costs.

The FTSE-listed firm maintained its expected adjusted operating margin for this year at 22.7% to 23,2%, excluding IFCN China.